Trilaciclib
Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively.. Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU chemotherapy[1].
Product Specifications
CAS Number
1374743-00-6
Product Name Alternative
G1T28
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Trilaciclib.html
Purity
99.42
Solubility
DMSO : 6.73 mg/mL (ultrasonic; warming; adjust pH to 5 with 1 M HCl; heat to 60°C)
Smiles
O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C)CC6)C=C5)N=C43)CCCCC2
Molecular Formula
C24H30N8O
Molecular Weight
446.55
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Semaphorin 5A (SEMA5A) activation kit by CRISPRa
SAR1 (SAR1A) (NM_001142648) Human Recombinant Protein
